Patent on neuro-degenerative drug to Suven Life Sciences - Prometheus IP

December 21, 2015by prometheusip0

Drug firm Suven Life Sciences has been granted a patent each by Eurasia, Europe, Israel and Macau for a drug used in the treatment of neuro-degenerative diseases. As of now, with the new patents, Suven has a total of 15 granted patents from Eurasia, 18 from Europe, 8 from Israel and 5 from Macau [more].

prometheusip

Prometheus IP is a leading intellectual property service enterprise offering competent and economic Intellectual Property Rights (IPR) solutions which include Patents, Designs, Copyrights and Trademarks.

Natco’s settlement of patent case with Gilead covering 30 mg, 45 mg and 75 mg versions of Tamiflu

Mixed ruling for Nobel Biocare on its patent infringement lawsuit against Neodent USA